Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702364 | 0.87 | CD274 (0.53) | CD274SMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL13702141 | 0.85 | HRH3 (0.60) | CD274SMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL13702310 | 0.85 | CD274 (0.57) | CD274SMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL13875951 | 0.85 | GAA (0.52) | CD274SMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL14058966 | 0.82 | KDM4E (0.55) | CD274SMN1; SMN2GAAALDH1A1KDM4E | |
| SCHEMBL13701717 | 0.78 | EPHX2 (0.63) | SMN1; SMN2GAAALDH1A1KDM4EEPHX2 | |
| SCHEMBL6932337 | 0.77 | GABRA5 (0.51) | SMN1; SMN2GABRA5EPHX2MEN1KMT2A | |
| SCHEMBL9906399 | 0.76 | SIGMAR1 (0.50) | ALDH1A1KDM4E | |
| SCHEMBL13701697 | 0.75 | MAPT (0.62) | GABRA5 | |
| SCHEMBL4191388 | 0.75 | EPHX2 (0.61) | CD274SMN1; SMN2ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | CD274 3768/4885SMN1; SMN2 4398/4885GAA 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.